Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $28,053 | 7 | 99.9% |
| Food and Beverage | $22.79 | 2 | 0.1% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Orexo US, Inc. | $28,053 | 7 | $0 (2023) |
| Indivior Inc. | $22.79 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $2,827 | 2 | Orexo US, Inc. ($2,827) |
| 2022 | $22,726 | 4 | Orexo US, Inc. ($22,726) |
| 2021 | $2,511 | 2 | Orexo US, Inc. ($2,500) |
| 2020 | $11.69 | 1 | Indivior Inc. ($11.69) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/06/2023 | Orexo US, Inc. | — | — | Cash or cash equivalent | $2,452.30 | Research |
| Study: OXD01-001 | ||||||
| 06/06/2023 | Orexo US, Inc. | — | — | Cash or cash equivalent | $375.00 | Research |
| Study: OXD01-001 | ||||||
| 10/06/2022 | Orexo US, Inc. | — | — | Cash or cash equivalent | $1,079.80 | Research |
| Study: OXD01-001 | ||||||
| 07/07/2022 | Orexo US, Inc. | — | — | Cash or cash equivalent | $5,428.80 | Research |
| Study: OXD01-001 | ||||||
| 04/21/2022 | Orexo US, Inc. | — | — | Cash or cash equivalent | $12,429.90 | Research |
| Study: OXD01-001 | ||||||
| 01/14/2022 | Orexo US, Inc. | — | — | Cash or cash equivalent | $3,787.20 | Research |
| Study: OXD01-001 | ||||||
| 12/20/2021 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $11.10 | General |
| Category: OUD | ||||||
| 11/18/2021 | Orexo US, Inc. | — | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: OXD01-001 | ||||||
| 07/23/2020 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $11.69 | General |
| Category: OUD | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| OXD01-001 | Orexo US, Inc. | $28,053 | 7 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 480 | 883 | $116,969 | $34,865 |
| 2022 | 7 | 470 | 975 | $129,445 | $37,537 |
| 2021 | 7 | 466 | 924 | $118,215 | $34,262 |
| 2020 | 8 | 496 | 900 | $107,978 | $26,721 |
All Medicare Procedures & Services
30 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 108 | 227 | $32,007 | $13,335 | 41.7% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 81 | 178 | $37,224 | $7,451 | 20.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 42 | 67 | $13,936 | $6,457 | 46.3% |
| 20552 | Injection of trigger points, 1-2 muscles | Office | 2023 | 78 | 134 | $20,502 | $3,031 | 14.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 39 | 39 | $8,112 | $2,664 | 32.8% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2023 | 96 | 188 | $1,880 | $1,017 | 54.1% |
| 20550 | Injection into tendon or ligament | Office | 2023 | 11 | 15 | $2,608 | $575.45 | 22.1% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 25 | 35 | $700.00 | $334.82 | 47.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 115 | 292 | $41,172 | $18,403 | 44.7% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2022 | 88 | 209 | $46,728 | $9,742 | 20.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 48 | 48 | $9,984 | $3,618 | 36.2% |
| 20552 | Injection of trigger points, 1-2 muscles | Office | 2022 | 82 | 155 | $23,760 | $3,491 | 14.7% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2022 | 111 | 241 | $2,553 | $1,187 | 46.5% |
| 20550 | Injection into tendon or ligament | Office | 2022 | 13 | 15 | $2,608 | $596.54 | 22.9% |
| 20553 | Injection of trigger points, 3 or more muscles | Office | 2022 | 13 | 15 | $2,640 | $499.70 | 18.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 112 | 278 | $39,198 | $18,075 | 46.1% |
| 20610 | Aspiration and/or injection of large joint or joint capsule | Office | 2021 | 91 | 202 | $43,164 | $8,616 | 20.0% |
| 20552 | Injections of trigger points in 1 or 2 muscles | Office | 2021 | 88 | 147 | $22,491 | $3,297 | 14.7% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 35 | 35 | $7,280 | $2,587 | 35.5% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2021 | 103 | 199 | $1,990 | $854.04 | 42.9% |
| 20553 | Injections of trigger points in 3 or more muscles | Office | 2021 | 17 | 19 | $3,344 | $615.63 | 18.4% |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | Office | 2021 | 20 | 44 | $748.00 | $218.11 | 29.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 113 | 216 | $30,456 | $10,741 | 35.3% |
| 20610 | Aspiration and/or injection of large joint or joint capsule | Office | 2020 | 103 | 189 | $44,946 | $8,114 | 18.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 43 | 47 | $9,776 | $2,641 | 27.0% |
About Dr. John Azzato, MD
Dr. John Azzato, MD is a Independent Medical Examiner healthcare provider based in Southport, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1811914435.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Azzato, MD has received a total of $28,076 in payments from pharmaceutical and medical device companies, with $2,827 received in 2023. These payments were reported across 9 transactions from 2 companies. The most common payment nature is "" ($28,053).
As a Medicare-enrolled provider, Azzato has provided services to 1,912 Medicare beneficiaries, totaling 3,682 services with total Medicare billing of $133,385. Data is available for 4 years (2020–2023), covering 30 distinct procedure/service records.
Practice Information
- Specialty Independent Medical Examiner
- Other Specialties General Practice, Orthopedic
- Location Southport, NC
- Active Since 07/17/2006
- Last Updated 08/26/2021
- Taxonomy Code 202C00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1811914435
Products in Payments
- SUBLOCADE (Drug) $22.79
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.